Joseph G. Oberlander, Ph.D., PMP., CAPM
CMC & Project Management
Dr. Joseph Oberlander is an experienced pharmaceutical program and project manager with deep expertise in clinical supply chain strategy and operations. With a strong scientific foundation in neuronal cell biology, synaptic physiology, and pre-clinical models of CNS and endocrine diseases, Dr. Oberlander brings a unique blend of technical knowledge and operational acumen to drug development programs.
His background spans medical device evaluation, small-molecule and biologics development for CNS and oncology indications, and clinical trial support. Dr. Oberlander excels in scientific project management, pre-clinical study design, analytical method development, and statistical data analysis. He also has a strong command of computational tools, including machine learning and advanced data visualization, and continuously stay informed through active engagement with scientific literature.
A collaborative leader and mentor, Dr. Oberlander is known for solving complex technical challenges with creativity and strategic insight, while fostering team growth and effective cross-functional communication.
Joseph G. Oberlander, Ph.D., PMP., CAPM's Recent Articles
Manufacturing Gaps in the U.S. Pharmaceutical Industry Exposed by Tariff Wars
The pharmaceutical supply chain is a globally interdependent network—one that has long relied on international trade to maintain affordability, innovation, and access. However, the intensification of tariff wars—particularly between the United States and countries like China, India, and Canada—is exposing…
Read Full Article
The Real Cost of Uncertainty: Why On-Again, Off-Again Tariffs Hurt Biotech Supply Chains
In drug development, and especially for smaller and medium-sized biotech companies, consistency is everything. From regulatory pathways to R&D timelines to global supply chains — predictability enables progress. But there’s one growing source of disruption that biotech leaders are increasingly…
Read Full Article
The U.S.-China Trade War and Its Impacts on Investigational Drug Supply Chains
The ongoing U.S.-China trade war, now entering its seventh year, has evolved beyond tariffs into a broader strategic contest over technology, industrial policy, and national security. For the pharmaceutical sector — particularly the supply chains evolved to manufacture investigational drugs…